Cargando…

Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome

The purpose of this trial was to clinically assess the effect and safety of Adipose Tissue-derived Stem Cells (ADSCs) treatment on primary Sjogren’s Syndrome (pSS). In this 6-month randomized, triple-blind, placebo-controlled clinical trial, pSS patients were randomly assigned to two groups. After d...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fangfang, Lu, Junhui, Shi, Xinlian, Li, Dongya, Zhou, Tingting, Jiang, Tianqi, Wang, Shengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439962/
https://www.ncbi.nlm.nih.gov/pubmed/37598237
http://dx.doi.org/10.1038/s41598-023-40802-5
_version_ 1785093070156464128
author Li, Fangfang
Lu, Junhui
Shi, Xinlian
Li, Dongya
Zhou, Tingting
Jiang, Tianqi
Wang, Shengming
author_facet Li, Fangfang
Lu, Junhui
Shi, Xinlian
Li, Dongya
Zhou, Tingting
Jiang, Tianqi
Wang, Shengming
author_sort Li, Fangfang
collection PubMed
description The purpose of this trial was to clinically assess the effect and safety of Adipose Tissue-derived Stem Cells (ADSCs) treatment on primary Sjogren’s Syndrome (pSS). In this 6-month randomized, triple-blind, placebo-controlled clinical trial, pSS patients were randomly assigned to two groups. After demographic characteristics and clinical examination were achieved, local injection of ADSCs into bilateral glands was performed with patients in ADSCs group (n = 35) and placebo solution was used for another group (n = 39) at three time points. Patients were followed up at 1-, 3- and 6-month. At each visit, studies of clinical and laboratory outcomes, as well as subjective symptoms, were conducted. A total of 74 subjects who met the including criteria were allocated in two groups and eventually 64 subjects (86.5%) completed the treatments and the follow-up assessments. Secretion of salivary and lachrymal glands were significantly improved in 3-month (P < 0.05). A great improvement of European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was found after ADSCs treatment with intergroup comparison from baseline to follow-up (P < 0.05). There is also a significant difference of European Alliance of Associations for Rheumatology SS Patient Reported Index (ESSPRI) between the two groups in the follow-up (P < 0.05). A significant abatement of IgG, IgM, C3, C4 and ESR between two groups was observed in part of follow-up time points (P < 0.05). The ADSCs therapy can provide relief of oral and eye’s dryness in our trial in a short time and has potential improvement of subjective and systemic syndromes of pSS.
format Online
Article
Text
id pubmed-10439962
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104399622023-08-21 Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome Li, Fangfang Lu, Junhui Shi, Xinlian Li, Dongya Zhou, Tingting Jiang, Tianqi Wang, Shengming Sci Rep Article The purpose of this trial was to clinically assess the effect and safety of Adipose Tissue-derived Stem Cells (ADSCs) treatment on primary Sjogren’s Syndrome (pSS). In this 6-month randomized, triple-blind, placebo-controlled clinical trial, pSS patients were randomly assigned to two groups. After demographic characteristics and clinical examination were achieved, local injection of ADSCs into bilateral glands was performed with patients in ADSCs group (n = 35) and placebo solution was used for another group (n = 39) at three time points. Patients were followed up at 1-, 3- and 6-month. At each visit, studies of clinical and laboratory outcomes, as well as subjective symptoms, were conducted. A total of 74 subjects who met the including criteria were allocated in two groups and eventually 64 subjects (86.5%) completed the treatments and the follow-up assessments. Secretion of salivary and lachrymal glands were significantly improved in 3-month (P < 0.05). A great improvement of European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was found after ADSCs treatment with intergroup comparison from baseline to follow-up (P < 0.05). There is also a significant difference of European Alliance of Associations for Rheumatology SS Patient Reported Index (ESSPRI) between the two groups in the follow-up (P < 0.05). A significant abatement of IgG, IgM, C3, C4 and ESR between two groups was observed in part of follow-up time points (P < 0.05). The ADSCs therapy can provide relief of oral and eye’s dryness in our trial in a short time and has potential improvement of subjective and systemic syndromes of pSS. Nature Publishing Group UK 2023-08-19 /pmc/articles/PMC10439962/ /pubmed/37598237 http://dx.doi.org/10.1038/s41598-023-40802-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Li, Fangfang
Lu, Junhui
Shi, Xinlian
Li, Dongya
Zhou, Tingting
Jiang, Tianqi
Wang, Shengming
Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title_full Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title_fullStr Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title_full_unstemmed Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title_short Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome
title_sort effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary sjogren’s syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439962/
https://www.ncbi.nlm.nih.gov/pubmed/37598237
http://dx.doi.org/10.1038/s41598-023-40802-5
work_keys_str_mv AT lifangfang effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT lujunhui effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT shixinlian effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT lidongya effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT zhoutingting effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT jiangtianqi effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome
AT wangshengming effectofadiposetissuederivedstemcellstherapyonclinicalresponseinpatientswithprimarysjogrenssyndrome